Gastroenterology
Digestive Disorders
AlcoholÂ’s Effect on Intestinal Lining
Gastroparesis (Medication Study)
Pancreatitis (Medication Study)
Ulcerative Colitis (Medication Study) Clinical Trial Protocol ID
Clinical Trial Investigator Name
Ali Keshavarzian, MD
Clinical Trial Title
A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of an Oral Investigational Drug in Patients with Mild to Moderate Ulcerative Colitis
Clinical Trial Protocol Description Once someone is determined to be eligible, they will return to Rush for Visit 1, where they will receive their initial dose of the study medication or placebo. The daily diary will need to be kept throughout the 12-week study. Five visits to Rush will take place over eight weeks. A follow-up telephone call will be made to each participant approximately 30 days after the last study visit for a follow-up discussion about health-related issues. Clinical Trial Eligibility Criteria - Men and women between the ages of 18 and 80 Diagnosis of active ulcerative colitis Not currently taking: more than 325 mg of aspirin a day; anti-coagulant therapy; oral or rectal steroids; five ASA rectal suppositories/enemas; or immunosuppressants
| |
|
